A Disruptive Innovation?

A Disruptive Innovation?

By Binod Dhakal, MD, MS “I just want to be a normal person, doctor,” Greg said, “but that’s not an option.” Greg, 58 years old, underwent hematopoietic stem cell transplantation (HSCT) for high-risk acute myeloid leukemia (AML) three years ago using cells from his...

Best Donor Choice: It’s in the Eye of the Beholder!

By Basem M. William, MD One of the major leaps in hematopoietic stem cell transplantation (HSCT) is the increasingly successful use of alternative donors, thereby allowing the delivery of a potentially curative transplant to approximately 75 percent of patients who do...